当前用于临床实践中的骨髓增殖性肿瘤评分系统
BCR::ABL1阴性骨髓增殖性肿瘤(MPN)的管理基于不同风险评以预防疾病进展相关事件并保持生活质量。本文综述各MPN亚型现有评分系统,比较其预测效能,并提出在临床实践中使用这些评分的算法。
要点
- MF患者预后较差,准确的总生存评分对选择HSCT至关重要。
- PV和ET中优先预测血管事件,因其发生率及相关的发病率和死亡率较高。
- 所有亚型均需评估生活质量;近年的评分已纳入分子危险因素。
核心结论
- 本文综述了MPN各风险现有的评分系统,并提出了在各MPN亚型临床实践中使用这些评分的算法。
研究设计与样本
- 综述:本文概述了MPN疾病进展相关事件的发生率,并对当前各风险可用的评分系统进行了详尽的比较综述。
主要发现
- MF患者预后更差,异基因造血干细胞移植(HSCT)是唯一治愈手段,但伴随高发病率和死亡率。
- PV和ET中血管事件发生率更高,其相关发病率和死亡率使血管事件预测成为优先。
- 过去数十年已开发出临床风险评分,近期评分纳入分子危险因素以实现更准确的风险分层。
关键数值与推荐
- BCR::ABL1阴性MPN由携带JAK-STAT通路激活驱动突变的髓系细胞增殖所致。
- MPN管理推荐基于对不同风险的评估,以预防疾病进展相关事件并保持患者生活质量。
- 风险可为所有MPN共有或各亚型特异(PV、ET、纤维化前MF和原发性MF)。
临床怎么用
- 作者提出算法以指导在每种MPN亚型临床实践中使用这些评分。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BCR::ABL1-negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies that are caused by the proliferation of myeloid cells that harbor a JAK-STAT pathway activating driver mutation. MPN management recommendations are based on the evaluation of different risks to prevent disease evolution-associated events while preserving patients' quality of life. Such risks can be common across all MPNs or specific to each subtype (polycythemia vera [PV], essential thrombocythemia [ET], prefibrotic myelofibrosis [MF], and primary MF). Patients with MF harbor the worse prognosis, and hematopoietic stem cell transplantation (HSCT) is the only curative treatment at the expense of a high rate of morbidity and mortality. Therefore, accurate scoring systems to estimate overall survival are crucial for the management of patients with MF and the selection for HSCT. In PV and ET, the prediction of vascular events is prioritized given their higher incidence and related morbidity and mortality. Finally, quality of life evaluation is important for all subtypes. To predict these risks and adapt MPN therapeutic strategies, clinical risk scores have been developed over the past decades and more recently have incorporated molecular risk factors for more accurate risk stratification. The large number of scoring systems available, combined with disease heterogeneity and the necessity to predict diverse outcomes, make it difficult for clinicians to choose the most appropriate score to evaluate their patients' risk in 2024. Here, we provide an overview of MPN disease evolution-associated event incidence and conduct an exhaustive comparative review of the scoring systems currently available for each risk. Finally, we propose an algorithm for the use of these scores in clinical practice in each MPN subtype.
引用
- Pasquer H, Kiladjian JJ, Benajiba L, et al. Current myeloproliferative neoplasm scoring systems for clinical practice. Blood. 2025. PMID: 39476004. doi:10.1182/blood.2024025459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。